ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -73.9% | -83.8% | -686.7% | |
| Return on assets | -17.7% | -53.9% | -253.7% | |
| Current ratio | 1.60 | 0.55 | 1.01 | |
| Debt to equity | 1.99 | 0.27 | – | |
| Net debt to EBITDA | 3.98× | -0.06× | – | |
| Interest coverage | -4.4× | -61.4× | 93.2× | |
| Capex to revenue | 1.9% | 0.7% | – | |
| Diluted shares | 11M | 2M | 6M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Ernexa Therapeutics generated $87.73M from operations and spent $876.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$87.73M
Used
$876.00K
Capital expenditure$876.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-7652.7%
×Asset turnover0.02×
×Equity multiplier13.83×
=Return on equity, FY2024-2264.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -7652.7% | 0.02× | 13.83× | -2264.3% |
| FY2023 | -31864.7% | 0.00× | 4.98× | -302.2% |
| FY2020 | -125.7% | 0.43× | 1.55× | -83.8% |
| FY2019 | -10.3% | 1.37× | 1.74× | -24.6% |
| FY2018 | -1.1% | 1.48× | 2.52× | -4.2% |
| FY2017 | -5.1% | 1.28× | 3.46× | -22.4% |
| FY2016 | -13.1% | 1.35× | 4.18× | -73.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$14.08M
- Cash generatingOperating cash flow above zero-$7.02M
- Return on assets improvedROA up on the prior year-90.7% → -267.3%
- Earnings backed by cashOperating cash flow above net income-$7.02M vs -$14.08M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.80 → 1.01
- No dilutionShare count did not rise1M → 6M
- Gross margin improvedGross margin up on the prior year83.51% → –
- More efficientAsset turnover rose0.01 → –